Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Thos...(uch commercialization and the company's ...),Health

Date:5/29/2009

uch commercialization, and the company's expectation that it will increase the clinical utility of its tests and expand its research and development efforts. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and potential delays associated with commercialization of a new test; the risks and uncertainties associated with the regulation of the company's tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

'/>"/>

SOURCE Genomic Health Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data
2. First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology
3. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
4. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
5. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
6. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
7. Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests
8. St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse
9. GEN Reports on the Trend Toward Predictive Toxicogenomics
10. Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
11. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay